利索-全球专利检索

  1. 登录
  2. 注册
发明授权
CN104232744B 人CIT基因和EGFR基因治疗肿瘤的用途及其相关药物 有权 转让

人CIT基因和EGFR基因治疗肿瘤的用途及其相关药物
摘要：
本发明涉及生物技术领域，具体公开了单独的人CIT基因；以及人CIT基因与人EGFR基因作为协同施药靶标，在制备或筛选肿瘤治疗药物中的用途。本发明还进一步构建了CIT基因小干扰RNA、CIT基因干扰慢病毒载体、CIT基因干扰慢病毒，并公开了他们在与EGFR基因协同治疗肿瘤中的用途。本发明提供的siRNA或者包含该siRNA序列的慢病毒载体、慢病毒能够特异性抑制人CIT基因和/或人EGFR基因的表达，尤其是慢病毒，本发明的CIT基因干扰慢病毒能单独、或者与EGFR基因干扰慢病毒协同抑制肿瘤细胞的生长，促进肿瘤细胞凋亡，在肿瘤治疗中具有重要意义。
摘要（英）：

The invention relates to the field of biotechnology and specifically discloses a separate human CIT gene and an application of the human CIT gene and a human EGFR gene used as synergistic drug targets in the preparation or screening of drugs for curing tumors. The invention also further constructs a CIT gene small interfering RNA, a CIT gene interfering lentiviral vector and a CIT gene interfering lentivirus and discloses an application of the CIT gene small interfering RNA, the CIT gene interfering lentiviral vector and the CIT gene interfering lentivirus in cooperation with the EGFR gene in curing tumors. The siRNA or the lentiviral vector containing siRNA sequence or the lentivirus containing siRNA sequence provided by the invention can inhibit expression of the human CIT gene and/or the human EGFR gene specifically, especially the lentivirus. The CIT gene interfering lentivirus can inhibit tumor cell growth and promote tumor cell apoptosis separately or in cooperation with the EGFR gene interfering lentivirus, and is of great significance in curing tumors.

公开/授权文献
0/0